Literature DB >> 11563986

A precursor form of vascular endothelial growth factor arises by initiation from an upstream in-frame CUG codon.

M K Tee1, R B Jaffe.   

Abstract

Vascular endothelial growth factor (VEGF) is a mitogen in physiological and pathological angiogenesis. Understanding the expression of different VEGF isoforms might be important for distinguishing angiogenesis in tissue development, vascular remodelling and tumour formation. We examined its expression and noted the presence of the isoforms VEGF(121) and VEGF(165) (121 and 165 residues long respectively) in fetal heart, lung, ovary, spleen, placenta and ovarian tumours. Unexpectedly, a 47 kDa species predominated in fetal intestine and muscle. The presumed initiation site in VEGF is an AUG codon (AUG(1039)), 1039 nt from its main transcriptional start site. AUG(1039) is preceded in the 5' untranslated region by an in-frame CUG at nt 499 (CUG(499)), which could produce the 47 kDa form with a 180-residue N-terminal extension. We therefore assessed whether CUG(499) functions as an initiator. CUG(499) initiation produced the 47 kDa VEGF(165) precursor, which was processed at two sites to yield VEGF and three N-terminal fragments. When CTG(499) was mutated to CGC, the precursor and N-terminal fragments were barely detectable. Although the precursor form was predominant in VEGF(165), both CUG(499) and AUG(1039) forms were found in VEGF(121). VEGF precursor induced neither the proliferation of human umbilical vein endothelial cells nor the expression of angiopoietin 2, which can be induced by, and act with, VEGF to induce tumour angiogenesis. The precursor also adheres to the extracellular matrix (ECM), suggesting that it might be a storage form for generating active VEGF in the cell or ECM. Alternate CUG(499) and AUG(1039) initiation and processing of the inactive precursor and its products might be important in regulating angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11563986      PMCID: PMC1222138          DOI: 10.1042/0264-6021:3590219

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  29 in total

1.  Initiation of translation at CUG, GUG, and ACG codons in mammalian cells.

Authors:  H Mehdi; E Ono; K C Gupta
Journal:  Gene       Date:  1990-07-16       Impact factor: 3.688

2.  Proteolytic processing regulates receptor specificity and activity of VEGF-C.

Authors:  V Joukov; T Sorsa; V Kumar; M Jeltsch; L Claesson-Welsh; Y Cao; O Saksela; N Kalkkinen; K Alitalo
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

3.  Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers.

Authors:  S A Stacker; K Stenvers; C Caesar; A Vitali; T Domagala; E Nice; S Roufail; R J Simpson; R Moritz; T Karpanen; K Alitalo; M G Achen
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

4.  Vascular endothelial growth factor is a secreted angiogenic mitogen.

Authors:  D W Leung; G Cachianes; W J Kuang; D V Goeddel; N Ferrara
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

5.  Vascular permeability factor, an endothelial cell mitogen related to PDGF.

Authors:  P J Keck; S D Hauser; G Krivi; K Sanzo; T Warren; J Feder; D T Connolly
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

6.  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing.

Authors:  E Tischer; R Mitchell; T Hartman; M Silva; D Gospodarowicz; J C Fiddes; J A Abraham
Journal:  J Biol Chem       Date:  1991-06-25       Impact factor: 5.157

7.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.

Authors:  J E Park; G A Keller; N Ferrara
Journal:  Mol Biol Cell       Date:  1993-12       Impact factor: 4.138

8.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

Authors:  K A Houck; N Ferrara; J Winer; G Cachianes; B Li; D W Leung
Journal:  Mol Endocrinol       Date:  1991-12

9.  In the human fetus, vascular endothelial growth factor is expressed in epithelial cells and myocytes, but not vascular endothelium: implications for mode of action.

Authors:  J L Shifren; N Doldi; N Ferrara; S Mesiano; R B Jaffe
Journal:  J Clin Endocrinol Metab       Date:  1994-07       Impact factor: 5.958

10.  PDGF-AA and PDGF-BB biosynthesis: proprotein processing in the Golgi complex and lysosomal degradation of PDGF-BB retained intracellularly.

Authors:  A Ostman; J Thyberg; B Westermark; C H Heldin
Journal:  J Cell Biol       Date:  1992-08       Impact factor: 10.539

View more
  13 in total

1.  The predicted truncation from a cancer-associated variant of the MSH2 initiation codon alters activity of the MSH2-MSH6 mismatch repair complex.

Authors:  Jennifer L Cyr; Graham D Brown; Jennifer Stroop; Christopher D Heinen
Journal:  Mol Carcinog       Date:  2011-08-11       Impact factor: 4.784

2.  The in vivo TRPV6 protein starts at a non-AUG triplet, decoded as methionine, upstream of canonical initiation at AUG.

Authors:  Claudia Fecher-Trost; Ulrich Wissenbach; Andreas Beck; Pascal Schalkowsky; Christof Stoerger; Janka Doerr; Anna Dembek; Martin Simon-Thomas; Armin Weber; Peter Wollenberg; Thomas Ruppert; Ralf Middendorff; Hans H Maurer; Veit Flockerzi
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

3.  N-VEGF, the Autoregulatory Arm of VEGF-A.

Authors:  Marina Katsman; Aviva Azriel; Guy Horev; Yitzhak Reizel; Ben-Zion Levi
Journal:  Cells       Date:  2022-04-11       Impact factor: 7.666

4.  High expression of a novel splicing variant of VEGF, L-VEGF144 in glioblastoma multiforme is associated with a poorer prognosis in bevacizumab treatment.

Authors:  Wen-Yu Cheng; Chiung-Chyi Shen; Ming-Tsang Chiao; Yea-Jiuan Liang; Tsuo-Fei Mao; Bai-Shuan Liu; Jun-Peng Chen
Journal:  J Neurooncol       Date:  2018-06-16       Impact factor: 4.130

5.  Truncated form of tenascin-X, XB-S, interacts with mitotic motor kinesin Eg5.

Authors:  Toshiya Endo; Hiroyoshi Ariga; Ken-ichi Matsumoto
Journal:  Mol Cell Biochem       Date:  2008-08-05       Impact factor: 3.842

Review 6.  VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level.

Authors:  Tania Arcondéguy; Eric Lacazette; Stefania Millevoi; Hervé Prats; Christian Touriol
Journal:  Nucleic Acids Res       Date:  2013-07-12       Impact factor: 16.971

7.  VEGF₁₂₁b and VEGF₁₆₅b are weakly angiogenic isoforms of VEGF-A.

Authors:  Raúl Catena; Leyre Larzabal; Marta Larrayoz; Eva Molina; Jose Hermida; Jackeline Agorreta; Ramon Montes; Ruben Pio; Luis M Montuenga; Alfonso Calvo
Journal:  Mol Cancer       Date:  2010-12-31       Impact factor: 27.401

Review 8.  Non-AUG translation initiation in mammals.

Authors:  Dmitry E Andreev; Gary Loughran; Alla D Fedorova; Maria S Mikhaylova; Ivan N Shatsky; Pavel V Baranov
Journal:  Genome Biol       Date:  2022-05-09       Impact factor: 17.906

9.  An upstream open reading frame within an IRES controls expression of a specific VEGF-A isoform.

Authors:  Amandine Bastide; Zeineb Karaa; Stéphanie Bornes; Corinne Hieblot; Eric Lacazette; Hervé Prats; Christian Touriol
Journal:  Nucleic Acids Res       Date:  2008-02-26       Impact factor: 16.971

10.  Neurons produce FGF2 and VEGF and secrete them at least in part by shedding extracellular vesicles.

Authors:  Gabriella Schiera; Patrizia Proia; Chiara Alberti; Marco Mineo; Giovanni Savettieri; Italia Di Liegro
Journal:  J Cell Mol Med       Date:  2007 Nov-Dec       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.